{"schema_version":"secwatch.filing_event.v1","accession":"0000898432-23-000117","form_type":"8-K","ticker":"OSRH","cik":"0001840425","company_name":"OSR Holdings, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.036705+00:00","generated_at":"2026-06-19T07:16:06.183989+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bellevue Life Sciences Acquisition Corp. closes IPO and full over-allotment, raising $69M","bullets":["IPO of 6M units at $10/unit closed Feb 14, 2023; over-allotment of 900K units exercised in full, total 6.9M units.","Gross proceeds of $69M from IPO and over-allotment; $70.2M placed in trust account including private placement.","Appointed five independent directors: Dr. Steven G. Reed (Chairman), Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, Mr. Jin Whan Park.","Units trade on Nasdaq under BLACU; common, warrants, rights under BLAC, BLACW, BLACR."],"urls":{"canonical":"https://secwatch.observer/filing/0000898432-23-000117","json":"https://secwatch.observer/filing/0000898432-23-000117.json","markdown":"https://secwatch.observer/filing/0000898432-23-000117.md","text":"https://secwatch.observer/filing/0000898432-23-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:16:06.183989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"127284dba3","claim":"Dr. Steven G. Reed was appointed as Chairman of the Board at OSR Holdings, Inc..","evidence_excerpt":"On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"3649d395b5","claim":"Dr. Rad Roberts was appointed as Director at OSR Holdings, Inc..","evidence_excerpt":"On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"70de417395","claim":"Dr. In Chul Chung was appointed as Director at OSR Holdings, Inc..","evidence_excerpt":"On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"719c8d5d69","claim":"Mr. Jin Whan Park was appointed as Director at OSR Holdings, Inc..","evidence_excerpt":"On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b15ed2e0bb","claim":"Mr. Hosun Euh was appointed as Director at OSR Holdings, Inc..","evidence_excerpt":"On February 14, 2023, in connection with Bellevue Life Sciences Acquisition Corp.’s (the “Company”) initial public offering (“IPO”), Dr. Steven G. Reed, Dr. In Chul Chung, Dr. Rad Roberts, Mr. Hosun Euh, and Mr. Jin Whan Park were each appointed to the board of directors of the Company (the “Board”) as independent directors, with Dr. Reed serving as Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840425/000089843223000117/0000898432-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}